JAK Inhibitors in Action: Effectiveness in Atopic Dermatitis

This is the second episode of our new "Program on JAK Inhibitors for Atopic Dermatitis" series, hosted by expert dermatologist Dr. Christopher Bunick, MD, PhD. This episode, "JAK Inhibitors in Action: Effectiveness in Atopic Dermatitis", featuring expert dermatologist Dr. James Song, MD, discusses the following topics: • Short- and long-term efficacy and safety data for JAK inhibitor therapies  • New topline data from the LEVEL UP trial studying upadacitinib in comparison to dupilumab for the treatment of patients aged 12 years and older with moderate-to-severe AD  • Head-to-head studies and real-world evidence evaluating JAK inhibitor therapies  • Emerging clinical developments and what's coming next in JAK inhibitor research

Join Today
Choosing the Right Path: JAK Inhibitors or Biologics for Atopic Dermatitis?
▶︎

Choosing the Right Path: JAK Inhibitors or Biologics for Atopic Dermatitis?

JAK inhibitors for IBD
▶︎

JAK inhibitors for IBD

JAK inhibitors in Psoriasis and PsA
▶︎

JAK inhibitors in Psoriasis and PsA

Examining the Gaps and Challenges in Diagnosing and Treating Prurigo Nodularis - Episode 1
▶︎

Examining the Gaps and Challenges in Diagnosing and Treating Prurigo Nodularis - Episode 1

Dermatologist Explains “Microdosing Accutane” | Does Low-Dose Isotretinoin Work?
▶︎

Dermatologist Explains “Microdosing Accutane” | Does Low-Dose Isotretinoin Work?

Conan O’Brien Delivers the Commencement Address | Harvard Commencement 2026
▶︎

Conan O’Brien Delivers the Commencement Address | Harvard Commencement 2026

467. “Your 10-Year-Old Self Is Still in There” | Brian Weisfeld on Creative Innovation
▶︎

467. “Your 10-Year-Old Self Is Still in There” | Brian Weisfeld on Creative Innovation

Exposing the Epidermolysis Bullosa Patient Burden and Challenges in Disease Management
▶︎

Exposing the Epidermolysis Bullosa Patient Burden and Challenges in Disease Management

10/18/22 JAK Inhibitors vs Biologics for Atopic Dermatitis
▶︎

10/18/22 JAK Inhibitors vs Biologics for Atopic Dermatitis

Rheumatologist Views on new FDA JAK inhibitor Boxed Warnings
▶︎

Rheumatologist Views on new FDA JAK inhibitor Boxed Warnings

Beyond the Filter: FSN Talks Kidney Care Topic: ADPKD: Genes Behind the Cysts
▶︎

Beyond the Filter: FSN Talks Kidney Care Topic: ADPKD: Genes Behind the Cysts

Hidradenitis Suppurativa: Defining Window of Opportunity for Moderate-to-Severe Patients
▶︎

Hidradenitis Suppurativa: Defining Window of Opportunity for Moderate-to-Severe Patients

The Quest for Itch Free, Clear Skin in Atopic Dermatitis New Practice Informing Evidence
▶︎

The Quest for Itch Free, Clear Skin in Atopic Dermatitis New Practice Informing Evidence

Neurodermitis: Diese neue Behandlungsmethode kann helfen I ARD Gesund
▶︎

Neurodermitis: Diese neue Behandlungsmethode kann helfen I ARD Gesund

Practical Symposium | JAK Inhibitor Therapy for Dermatologic Disorders by Neal Bhatia, MD
▶︎

Practical Symposium | JAK Inhibitor Therapy for Dermatologic Disorders by Neal Bhatia, MD

Mechanism of Action of JAK Inhibitors
▶︎

Mechanism of Action of JAK Inhibitors

Treating and Managing Atopic Dermatitis with Matthew Zirwas, MD
▶︎

Treating and Managing Atopic Dermatitis with Matthew Zirwas, MD

Eczema's 5 step plan to natural healing
▶︎

Eczema's 5 step plan to natural healing

JAK Inhibitors (Xeljanz, Rinvoq, Baricitinib) For Arthritis Treatment
▶︎

JAK Inhibitors (Xeljanz, Rinvoq, Baricitinib) For Arthritis Treatment

IL 31 Mechanism of Action and Clinical Implications for Prurigo Nodularis
▶︎

IL 31 Mechanism of Action and Clinical Implications for Prurigo Nodularis